Posttransplant lymphomas

Jennifer A. Kanakry; Yvette L. Kasamon; Richard F. Ambinder

doi:10.1007/978-1-62703-408-1_17

Posttransplant lymphomas

Jennifer A. Kanakry, Yvette L. Kasamon, Richard F. Ambinder

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.

Original language	English (US)
Title of host publication	Lymphoma
Subtitle of host publication	Diagnosis and Treatment
Publisher	Humana Press Inc.
Pages	267-277
Number of pages	11
ISBN (Electronic)	9781627034081
ISBN (Print)	9781627034074
DOIs	https://doi.org/10.1007/978-1-62703-408-1_17
State	Published - Jan 1 2013

Keywords

Epstein-Barr virus (EBV)
Hematopoietic stem cell transplantation (HSCT)
Immune suppression
Posttransplantation lymphoproliferative disorders (PTLDs)
Solid organ transplantation (SOT)

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-62703-408-1_17

Cite this

@inbook{bc39a5756d6f426f813e22c16d51dcc7,

title = "Posttransplant lymphomas",

abstract = "PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.",

keywords = "Epstein-Barr virus (EBV), Hematopoietic stem cell transplantation (HSCT), Immune suppression, Posttransplantation lymphoproliferative disorders (PTLDs), Solid organ transplantation (SOT)",

author = "Kanakry, {Jennifer A.} and Kasamon, {Yvette L.} and Ambinder, {Richard F.}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC 2013.",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-1-62703-408-1_17",

language = "English (US)",

isbn = "9781627034074",

pages = "267--277",

booktitle = "Lymphoma",

publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Posttransplant lymphomas

AU - Kanakry, Jennifer A.

AU - Kasamon, Yvette L.

AU - Ambinder, Richard F.

N1 - Publisher Copyright: © Springer Science+Business Media, LLC 2013.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.

AB - PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.

KW - Epstein-Barr virus (EBV)

KW - Hematopoietic stem cell transplantation (HSCT)

KW - Immune suppression

KW - Posttransplantation lymphoproliferative disorders (PTLDs)

KW - Solid organ transplantation (SOT)

UR - http://www.scopus.com/inward/record.url?scp=85032832199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032832199&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-408-1_17

DO - 10.1007/978-1-62703-408-1_17

M3 - Chapter

AN - SCOPUS:85032832199

SN - 9781627034074

SP - 267

EP - 277

BT - Lymphoma

PB - Humana Press Inc.

ER -

Posttransplant lymphomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this